Financial Perspectives Inc Reduces Holdings in Boston Scientific Corporation $BSX

Key Points

• Financial Perspectives Inc reduced its holdings in Boston Scientific Corporation by 2.2%, owning 134,150 shares valued at approximately $14.4 million after selling 3,042 shares in the second quarter.
• Boston Scientific reported a 22.8% revenue increase year-over-year, with earnings per share of $0.75 surpassing analyst estimates of $0.72.
• Institutional investors own 89.07% of Boston Scientific, with significant investments from firms like GAMMA Investing LLC and Brighton Jones LLC, indicating strong institutional support for the stock.

Financial Perspectives Inc reduced its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,150 shares of the medical equipment provider's stock after selling 3,042 shares during the quarter. Boston Scientific accounts for approximately 4.4% of Financial Perspectives Inc's investment portfolio, making the stock its 5th biggest holding. Financial Perspectives Inc's holdings in Boston Scientific were worth $14,409,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Brighton Jones LLC raised its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock valued at $2,578,000 after purchasing an additional 3,745 shares during the period. Blue Trust Inc. raised its position in shares of Boston Scientific by 13.0% in the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after purchasing an additional 575 shares during the period. Advisor Resource Council bought a new position in shares of Boston Scientific in the first quarter valued at about $283,000. Finally, Appleton Partners Inc. MA bought a new position in shares of Boston Scientific in the first quarter valued at about $204,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 1.5%

BSX opened at $99.20 on Monday. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market capitalization of $146.99 billion, a price-to-earnings ratio of 59.05, a PEG ratio of 2.39 and a beta of 0.61. The company's 50 day moving average price is $101.29 and its two-hundred day moving average price is $101.77.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the firm posted $0.62 EPS. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Truist Financial raised their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Robert W. Baird raised their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 1st. BTIG Research increased their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific has an average rating of "Buy" and an average price target of $120.71.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.